JP2014520105A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014520105A5 JP2014520105A5 JP2014513858A JP2014513858A JP2014520105A5 JP 2014520105 A5 JP2014520105 A5 JP 2014520105A5 JP 2014513858 A JP2014513858 A JP 2014513858A JP 2014513858 A JP2014513858 A JP 2014513858A JP 2014520105 A5 JP2014520105 A5 JP 2014520105A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- polymer according
- tumor
- group
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims 38
- 239000000203 mixture Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 14
- 239000013543 active substance Substances 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000003795 chemical substances by application Substances 0.000 claims 9
- 239000000412 dendrimer Substances 0.000 claims 9
- 229920000736 dendritic polymer Polymers 0.000 claims 9
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000005647 linker group Chemical group 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 125000003277 amino group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 229960003604 testosterone Drugs 0.000 claims 3
- 231100000419 toxicity Toxicity 0.000 claims 3
- 230000001988 toxicity Effects 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 230000001387 anti-histamine Effects 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 230000000903 blocking effect Effects 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 210000004899 c-terminal region Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 239000003246 corticosteroid Substances 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 2
- 210000003128 head Anatomy 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 229920000053 polysorbate 80 Polymers 0.000 claims 2
- 229940068968 polysorbate 80 Drugs 0.000 claims 2
- 238000009101 premedication Methods 0.000 claims 2
- 208000023958 prostate neoplasm Diseases 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 230000003381 solubilizing effect Effects 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 239000004094 surface-active agent Substances 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010065553 Bone marrow failure Diseases 0.000 claims 1
- 208000014644 Brain disease Diseases 0.000 claims 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000032274 Encephalopathy Diseases 0.000 claims 1
- 206010016807 Fluid retention Diseases 0.000 claims 1
- 108700012941 GNRH1 Proteins 0.000 claims 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 claims 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 1
- 206010019851 Hepatotoxicity Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 102000009151 Luteinizing Hormone Human genes 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 206010028116 Mucosal inflammation Diseases 0.000 claims 1
- 201000010927 Mucositis Diseases 0.000 claims 1
- 208000000112 Myalgia Diseases 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 206010029155 Nephropathy toxic Diseases 0.000 claims 1
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 206010033109 Ototoxicity Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010038687 Respiratory distress Diseases 0.000 claims 1
- 206010040914 Skin reaction Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000025371 Taste disease Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims 1
- 229960001573 cabazitaxel Drugs 0.000 claims 1
- 229940127093 camptothecin Drugs 0.000 claims 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims 1
- 230000005907 cancer growth Effects 0.000 claims 1
- 231100000259 cardiotoxicity Toxicity 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 238000013270 controlled release Methods 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 208000002173 dizziness Diseases 0.000 claims 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 206010016256 fatigue Diseases 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 claims 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 239000002434 gonadorelin derivative Substances 0.000 claims 1
- 231100000226 haematotoxicity Toxicity 0.000 claims 1
- 231100000304 hepatotoxicity Toxicity 0.000 claims 1
- 230000007686 hepatotoxicity Effects 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 150000002431 hydrogen Chemical class 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 201000002364 leukopenia Diseases 0.000 claims 1
- 231100001022 leukopenia Toxicity 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000026721 nail disease Diseases 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
- 230000007694 nephrotoxicity Effects 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 231100000228 neurotoxicity Toxicity 0.000 claims 1
- 230000007135 neurotoxicity Effects 0.000 claims 1
- 208000004235 neutropenia Diseases 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 231100000262 ototoxicity Toxicity 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000035483 skin reaction Effects 0.000 claims 1
- 231100000430 skin reaction Toxicity 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 235000019669 taste disorders Nutrition 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 230000037317 transdermal delivery Effects 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161493886P | 2011-06-06 | 2011-06-06 | |
| US61/493,886 | 2011-06-06 | ||
| PCT/AU2012/000647 WO2012167309A1 (en) | 2011-06-06 | 2012-06-06 | Macromolecules |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014520105A JP2014520105A (ja) | 2014-08-21 |
| JP2014520105A5 true JP2014520105A5 (OSRAM) | 2015-07-23 |
| JP6158177B2 JP6158177B2 (ja) | 2017-07-05 |
Family
ID=47295262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014513858A Active JP6158177B2 (ja) | 2011-06-06 | 2012-06-06 | 高分子 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9744246B2 (OSRAM) |
| EP (1) | EP2729179B1 (OSRAM) |
| JP (1) | JP6158177B2 (OSRAM) |
| KR (1) | KR101941318B1 (OSRAM) |
| CN (2) | CN110124051B (OSRAM) |
| AU (1) | AU2012267200B2 (OSRAM) |
| BR (1) | BR112013031556B1 (OSRAM) |
| CA (1) | CA2837979C (OSRAM) |
| DK (1) | DK2729179T3 (OSRAM) |
| ES (1) | ES2834992T3 (OSRAM) |
| HR (1) | HRP20201998T1 (OSRAM) |
| HU (1) | HUE052285T2 (OSRAM) |
| IN (1) | IN2014DN00101A (OSRAM) |
| LT (1) | LT2729179T (OSRAM) |
| PL (1) | PL2729179T3 (OSRAM) |
| PT (1) | PT2729179T (OSRAM) |
| SI (1) | SI2729179T1 (OSRAM) |
| WO (1) | WO2012167309A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180326081A1 (en) * | 2011-06-06 | 2018-11-15 | Starpharma Pty Ltd | Macromolecules |
| US20160221992A1 (en) * | 2013-05-16 | 2016-08-04 | Universite De Strasbourg | Dendritic compounds including a chelating, fluorochrome or recognition agent, compositions including same and uses thereof |
| US20160220689A1 (en) * | 2013-09-10 | 2016-08-04 | Starpharma Pty Ltd. | Macromolecules of dendrimer-platinum conjugates |
| EP3152248B1 (en) | 2014-06-06 | 2019-10-09 | Starpharma Pty Ltd | Dendrimer-drug conjugates |
| CN108135881B (zh) | 2015-08-11 | 2020-11-13 | 同宜医药（苏州）有限公司 | 多配体药物偶联体及其用途 |
| CN106554330B (zh) * | 2015-09-26 | 2019-07-05 | 南京友怡医药科技有限公司 | 水溶性多西他赛抗癌药物化合物及其制备方法和应用 |
| CN106554329B (zh) * | 2015-09-26 | 2019-07-05 | 南京友怡医药科技有限公司 | 水溶性紫杉醇抗癌药物化合物及其制备方法和应用 |
| WO2017068051A1 (en) * | 2015-10-21 | 2017-04-27 | Lek Pharmaceuticals D.D. | Peg-based dendron and process for producing the same |
| WO2017135893A1 (en) * | 2016-02-05 | 2017-08-10 | Nipsea Technologies Pte Ltd | Aqueous dendritic amine coatings |
| WO2017196986A1 (en) * | 2016-05-10 | 2017-11-16 | Massachusetts Institute Of Technology | Dendrimer-drug conjugates, hydrogel compositions, and methods |
| JOP20190191A1 (ar) * | 2017-02-22 | 2019-08-08 | Astrazeneca Ab | وحدات شجرية علاجية |
| EP3778628A4 (en) * | 2018-03-29 | 2021-11-24 | NOF Corporation | DEGRADABLE POLYETHYLENE GLYCOL CONJUGATE |
| MX2021000677A (es) * | 2018-07-19 | 2021-03-25 | Starpharma Pty Ltd | Dendrimero terapeutico. |
| US12071517B2 (en) | 2018-07-19 | 2024-08-27 | Starpharma Pty Ltd. | Therapeutic dendrimer |
| TWI856967B (zh) | 2018-08-17 | 2024-10-01 | 瑞典商阿斯特捷利康公司 | 樹枝狀體配製物 |
| TWI831817B (zh) * | 2018-08-17 | 2024-02-11 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| SG11202104239XA (en) * | 2018-11-20 | 2021-06-29 | Starpharma Pty Ltd | Therapeutic dendrimer |
| SG11202104309RA (en) * | 2018-11-29 | 2021-06-29 | Starpharma Pty Ltd | Dendrimer for therapy and imaging |
| EP4021511A4 (en) * | 2019-08-28 | 2023-10-04 | Starpharma Pty Ltd | TARGETED DENDRIMER CONJUGATES |
| KR20220072851A (ko) * | 2019-09-26 | 2022-06-02 | 스타파마 피티와이 리미티드 | 치료용 덴드리머 |
| WO2021213492A1 (zh) * | 2020-04-24 | 2021-10-28 | 上海森辉医药有限公司 | 一类载药的大分子及其制备方法 |
| CA3180877A1 (en) * | 2020-06-03 | 2021-12-09 | Starpharma Pty Ltd | Therapeutic conjugates |
| BR112023002855A2 (pt) * | 2020-08-25 | 2023-04-25 | Shanghai Senhui Medicine Co Ltd | Macromolécula carregada com fármaco e método de preparação para a mesma |
| US20230263900A1 (en) * | 2020-08-31 | 2023-08-24 | Starpharma Pty Ltd. | Dendrimer-drug conjugate |
| CN116194091B (zh) * | 2020-09-24 | 2025-04-18 | 视尔普斯眼科公司 | 包含水凝胶和环孢菌素的持续释放可生物降解泪小管内插入物 |
| WO2022066891A1 (en) * | 2020-09-24 | 2022-03-31 | Ocular Therapeutix, Inc. | Sustained release biodegradable intracanalicular inserts comprising a hydrogel and an active agent |
| CN117164357B (zh) * | 2023-01-03 | 2024-07-19 | 广东捷成科创电子股份有限公司 | 一种五元系大功率型压电陶瓷材料及其制备方法 |
| TW202448514A (zh) * | 2023-05-08 | 2024-12-16 | 大陸商上海森輝醫藥有限公司 | 抗真菌藥的載藥大分子及其製備方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840900A (en) * | 1993-10-20 | 1998-11-24 | Enzon, Inc. | High molecular weight polymer-based prodrugs |
| US7261875B2 (en) * | 2001-12-21 | 2007-08-28 | Board Of Regents, The University Of Texas System | Dendritic poly (amino acid) carriers and methods of use |
| CN101102787A (zh) * | 2004-08-09 | 2008-01-09 | 艾丽奥斯生物制药有限公司 | 合成的超糖基化、抗蛋白酶的多肽变体、口服制剂及其使用方法 |
| CN104524596B (zh) | 2006-01-20 | 2018-10-09 | 星药股份有限公司 | 经修饰的大分子 |
| CN101002945B (zh) * | 2006-01-20 | 2012-09-05 | 清华大学 | 一种用于肿瘤治疗的新型复合物 |
| WO2008017125A1 (en) * | 2006-08-11 | 2008-02-14 | Starpharma Pty Ltd | Targeted polylysine dendrimer therapeutic agent |
| WO2009158668A1 (en) | 2008-06-26 | 2009-12-30 | Prolynx Llc | Prodrugs and drug-macromolecule conjugates having controlled drug release rates |
| WO2011072290A2 (en) * | 2009-12-11 | 2011-06-16 | The Regents Of The University Of Michigan | Targeted dendrimer-drug conjugates |
| US8946405B2 (en) | 2010-05-05 | 2015-02-03 | Prolynx Llc | Controlled release from solid supports |
| EP2571496A4 (en) | 2010-05-05 | 2016-03-30 | Prolynx Llc | CONTROLLED RELEASE OF MEDICINE FROM DENIMERS |
| DK2566335T3 (en) | 2010-05-05 | 2016-10-03 | Prolynx Llc | Controlled release of active ingredients from macromolecular CONJUGATES |
-
2012
- 2012-06-06 ES ES12797060T patent/ES2834992T3/es active Active
- 2012-06-06 PT PT127970606T patent/PT2729179T/pt unknown
- 2012-06-06 US US14/124,651 patent/US9744246B2/en active Active
- 2012-06-06 HU HUE12797060A patent/HUE052285T2/hu unknown
- 2012-06-06 HR HRP20201998TT patent/HRP20201998T1/hr unknown
- 2012-06-06 IN IN101DEN2014 patent/IN2014DN00101A/en unknown
- 2012-06-06 AU AU2012267200A patent/AU2012267200B2/en active Active
- 2012-06-06 EP EP12797060.6A patent/EP2729179B1/en active Active
- 2012-06-06 CN CN201910456157.8A patent/CN110124051B/zh active Active
- 2012-06-06 SI SI201231865T patent/SI2729179T1/sl unknown
- 2012-06-06 LT LTEP12797060.6T patent/LT2729179T/lt unknown
- 2012-06-06 DK DK12797060.6T patent/DK2729179T3/da active
- 2012-06-06 PL PL12797060T patent/PL2729179T3/pl unknown
- 2012-06-06 WO PCT/AU2012/000647 patent/WO2012167309A1/en not_active Ceased
- 2012-06-06 CN CN201280038437.3A patent/CN103796684B/zh active Active
- 2012-06-06 BR BR112013031556-3A patent/BR112013031556B1/pt active IP Right Grant
- 2012-06-06 JP JP2014513858A patent/JP6158177B2/ja active Active
- 2012-06-06 KR KR1020147000115A patent/KR101941318B1/ko active Active
- 2012-06-06 CA CA2837979A patent/CA2837979C/en active Active
-
2017
- 2017-08-28 US US15/688,780 patent/US10265409B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014520105A5 (OSRAM) | ||
| Abolmaali et al. | A review of therapeutic challenges and achievements of methotrexate delivery systems for treatment of cancer and rheumatoid arthritis | |
| JP6158177B2 (ja) | 高分子 | |
| Zhou et al. | Linear-dendritic drug conjugates forming long-circulating nanorods for cancer-drug delivery | |
| Gu et al. | Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma | |
| KR102811484B1 (ko) | 치료 덴드리머 | |
| JP6595463B2 (ja) | 気道に影響する増殖性疾患の処置に有用な製剤 | |
| Taheri et al. | The in vivo antitumor activity of LHRH targeted methotrexate–human serum albumin nanoparticles in 4T1 tumor-bearing Balb/c mice | |
| Wong et al. | Linear-like polypeptide-based micelle with pH-sensitive detachable PEG to deliver dimeric camptothecin for cancer therapy | |
| CN113613680A (zh) | 用于增强癌症免疫疗法的与免疫检查点抑制剂复合的树枝状聚合物 | |
| Shi et al. | Ascorbic palmitate as a bifunctional drug and nanocarrier of paclitaxel for synergistic anti-tumor therapy | |
| Maji et al. | Polymeric nanomaterials: Fundamentals and therapeutic applications | |
| CN114025743B (zh) | 含有混合聚合物胶束的药物组合物 | |
| Girase et al. | Design of surface tailored carboxymethyl dextran-protein based nanoconjugates for paclitaxel: Spectroscopical characterizations and cytotoxicity assay | |
| WO2022042583A1 (zh) | 载药的大分子及其制备方法 | |
| JP2023500602A (ja) | ペプチド－ナノ粒子コンジュゲート 〔関連出願の相互参照〕 本出願は、２０１９年１０月２９日に出願されたｐｃｔ／ｕｓ２０１９／０５８４６３の一部継続出願であり、２０１９年１０月２９日に出願された米国仮出願第６２／９２７，２９３号の優先権を主張し、その全体が参照により本明細書に組み込まれる。 | |
| TW201807025A (zh) | 主動標靶型高分子衍生物、包含該高分子衍生物之組合物、及其等之用途 | |
| US12071517B2 (en) | Therapeutic dendrimer | |
| Lather et al. | Polymeric micelles of modified chitosan block copolymer as nanocarrier for delivery of paclitaxel | |
| AU2014215555B2 (en) | Nanoparticles containing a taxane and their use | |
| Gingras et al. | Degradable dendrimers for drug delivery | |
| Momekova et al. | NANO-SIZED DRUG DELIVERY PLATFORMS FOR TAXANE ANTINEOPLASTIC AGENTS | |
| HK40080640A (en) | Peptide-nanoparticle conjugates | |
| HK40060279A (en) | Dendritic polymers complexed with immune checkpoint inhibitors for enhanced cancer immunotherapy |